Maravai LifeSciences (MRVI) investor relations material

Key achievements and operational reset

• Over $65 million in costs removed, exceeding original targets and driving EBITDA savings.

• Organizational streamlining improved alignment across commercial, operations, and quality functions.

• Commercial execution led to improved order visibility and trajectory, especially in GMP and discovery.

• Introduction of ModTail generated strong traction with large pharma and biotech customers.

• Achieved $65 million in Q1 revenue, $20 million EBITDA, and positive free cash flow for the first time in six quarters.

Commercial execution and demand trends

• Demand improvement attributed primarily to enhanced commercial execution rather than macro funding shifts.

• Segmentation of discovery orders allowed sales reps to focus on larger deals, boosting order velocity.

• Discovery business shows healthy growth, with a 70/30 split favoring larger ($15K+) orders.

• Academic customers represent less than 5% of business, minimizing exposure to that segment.

Product and innovation pipeline

• CleanCap remains a major revenue driver, with ModTail and custom mRNA products gaining momentum.

• GMP enzymes and oligos, though smaller, are experiencing growth.

• ModTail's GMP launch is expected by year-end, with robust demand and potential to match CleanCap's growth trajectory.

• MockV product granted a new U.S. patent, supporting IP strength and continued double-digit growth.